The rise of Viagra and its influence on the pharmaceutical landscape presents a complicated question for traders. While the early sales data were impressive, the exclusivity has lapsed, leading to a deluge of off-brand alternatives that are chipping here away at revenue. Furthermore, the sector is facing difficulties related to aging trends and shi